[ad_1]
Scientists from the Tuberculosis Vaccine Initiative SA (SATVI) and the Desmond Tutu HIV Foundation announced the results of an innovative clinical trial conducted in Worcester and Cape Town.
The test tested the ability of Bacillus Calmette-Guerin (BCG) and the new candidate vaccine H4: IC31 to help prevent an initial or sustained TB infection. This was the first randomized controlled prospective trial to determine whether vaccination can prevent Mycobacterium tuberculosis (MTB) infection in healthy and high-risk adolescents.
The BCG vaccine is nearly 100 years old. A single dose at birth is moderately effective in preventing severe TB in infants and young children, but does not adequately protect adolescents and adults who are at greatest risk of developing and spreading TB.
A dose of BCG (revaccination) for adolescents could provide protection against MTB infection.
BCG has shown a significant ability to help people control or eliminate TB infection. BCG has shown its effectiveness in preventing persistent TB infections – which means that participants initially tested positive for TB were more likely to have eliminated or controlled the infection within six months.
In this study, revaccination with a vaccine efficacy of 45.4%
The trend observed for H4: IC31 is the first time that a subunit vaccine has shown any sign that it has been observed. he might be able to protect against tubercular infection or disease in humans
Mark Hatherill, a researcher in this study, said, "Although neither of the two vaccines has been statistically significant in the prevention of an initial tuberculosis infection, we are extremely encouraged by the results of the efficacy against persistent tuberculosis infections. We believe that the findings will provide a significant scientific benefit to the field to understand the protection against tuberculosis infection. "
The study was approved by the Medicines Control Council of SA and the Independent Ethics Committee of the UCT. [email protected]
[ad_2]
Source link
